(PM P11) Carboplatin Hyperthermic Intraperitoneal Chemotherapy is Safe and Efficacious in Recurrent and Advanced Ovarian Cancer
Saturday, February 15, 2020
12:05 PM – 12:10 PM
INTRODUCTION Cisplatin HIPEC in recurrent and advanced ovarian cancer (AOC) improves survival, but renal toxicity is common, even with renal protectants. Carboplatin IV/IP has less nephrotoxicity with comparable efficacy. This study reports the safety, efficacy of carboplatin HIPEC. METHODS Retrospective analysis of a CRS/HIPEC registry identified 34 recurrent and AOC patients. HIPEC with carboplatin (600-800 mg/mM2) was delivered for 90 minutes at 41-42 C. PCI, CC-score, nephrotoxicity by RIFLE score, thrombocytopenia, pancytopenia, length of stay (LOS), PFS, OS, peritoneal relapse and all relapse events were collected and compared from the date of surgery. RESULTS 34 recurrent and AOC patients had CRS, 21 treated with HIPEC. Mean PCI was 25 for both CRS and CRS/HIPEC, 92% HIPEC and 90% no HIPEC had CC0/1. No major nephrotoxicity occurred. Thrombocytopenia (platelet < 50K) occurred in 11% of HIPEC patients. LOS was 9.5 days for both groups. OS was 20 vs. 56 months for CRS vs. CRS/HIPEC p<0.01. There was no difference in median OS in HIPEC group treated at recurrence or first CRS. Peritoneal recurrence was 69% for CRS vs 33% for CRS/HIPEC p<0.01. CONCLUSION Carboplatin HIPEC has similar efficacy to cisplatin without the nephrotoxicity. Carboplatin HIPEC for recurrent and AOC is safe and efficacious. The survival benefit may be attributable to peritoneal disease control and peritoneal relapse free survival may be a viable endpoint in future HIPEC clinical trials.